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Summary 
T  cell tolerance to self is achieved by deletion or inactivation of clones recognizing peptides of 
self proteins presented by major histocompatibility complex molecules. A considerable fraction 
of self proteins accessible to the immune system is contributed by the system itself, for example, 
the receptors used for antigen recognition (antibodies and T  cell receptors [TCKs]).  Thus far, 
it has remained unclear, whether antigen receptors are subject to self tolerance, or on contrary, 
engage into network interactions  implying immunity rather than tolerance.  In this study, we 
demonstrate self tolerance to synthetic peptides corresponding to the first hypervariable region 
of the V~ 8.1 and VB 8.2 TCK proteins.  We also show that the tolerogenic synthetic peptide 
corresponds  to a fragment  produced by processing of the V/3 protein,  and conversely, that  a 
V~ peptide not produced by processing is also not subject to self tolerance.  Thus,  the rules of 
tolerance seem to apply to antigen receptors,  at least to their germline-encoded portions,  in a 
similar fashion as to other self proteins.  This finding has important  implications for studies of 
natural  and artificially induced immune  networks. 
D 
iscrimination between self and nonself is a salient fea- 
ture of the immune  system.  At the T  cell level,  this 
is achieved  by inactivation  and/or deletion of clones recog- 
nizing peptides of self proteins presented by MHC molecules 
(1-5). Part of the diverse array of self proteins accessible  to 
the immune system is provided by the system itself, for ex- 
ample, the receptors (antibodies and TCR) used for antigen 
recognition. Nevertheless, self tolerance to antigen receptors 
has not been demonstrated thus far. In contrast, network in- 
teractions implying immunity rather  than tolerance to self 
receptors have been postulated and reported (6-9). We there- 
fore designed an experimental model that could, in principle, 
answer  the  question  of whether  self tolerance  to  antigen 
receptors operates under physiological conditions.  Our ap- 
proach has been to investigate the immunogenicity of pep- 
tides that are unique to TCK V~ proteins that are expressed 
in certain mouse strains but not in others. The defect in ex- 
pressing these proteins can be twofold: first,  a large genomic 
deletion of 50% of V~ genes from chromosome 6 referred 
to as the TCK-V~ a allele,  carried by several inbred mouse 
strains (10), and second, clonal deletion of T cells expressing 
particular  V~ proteins by endogenous superantigens  (1, 2) 
early in ontogeny in the thymus. Mice expressing or deleting 
a particular VB were immunized with synthetic peptides de- 
rived from that V~ sequence, and a correlation was sought 
between the pattern of responsiveness and the expression of 
the V/3 protein.  We report here self tolerance to sequences 
corresponding to the first hypervariable region of the V~ 8.1 
and V~ 8.2 proteins. 
Materials  and Methods 
Mice and Immunizations.  Mice were obtained from The Jackson 
Laboratories (Bar Harbor, ME), except strain B10.Q-V/~' (obtained 
from  Dr.  C.  David,  Mayo Clinic,  Rochester,  MN).  F1 hybrids 
were bred in our facilities. Mice, >8 wk of age, were injected with 
35 nmol of peptide antigen in CFA in the hind footpads and tailbase. 
Peptides.  Peptides were prepared by solid-phase synthesis and 
purified by reverse-phase HPLC; their homogeneity was confirmed 
by analytical HPLC, amino acid analysis, and fast atom bombard- 
ment mass spectroscopy. 
Soluble Single-chain TCR.  The TCR Vc~4  and V~8.2 genes were 
isolated from T hybridoma 1934.4 (11) by PCR using oligonucleo- 
tides as described (12). The V genes were cloned into phsmid vectors 
designed for expression and secretion ofimmunoglobulin domains 
by Escherichia coli (13). For the single-chain construct,  the COOH 
terminus of Vc~ was joined to the NHz terminus of Vfl by a (Gly4 
Set)3 linker. A COOH-terminal  His# tag was inserted  to allow 
affinity purification on Ni2+-NTA agarose columns. The strategy 
for construction of plasmids with single V genes and joined Vc~V~ 
genes was described previously (14). The single chain TCtL con- 
struct was secreted by recombinant E. coli at 0.5-1 mg/liter,  and 
the Vot construct at 2 rag/liter (the VB construct alone was poorly 
secreted; references 12,  14). Circular  dichroism  analyses of the 
249  J. Exp. Med. ￿9  The Rockefeller  University Press - 0022-1007/95/07/0249/06 $2.00 








t  ￿9  ￿9 
~  --'-.'-  ...... 
,[  ,  ,  ,  ,  ,  ,  ,  , 
01234667891011  Stimulation index 
Stimulation  Index 
B  10.BR  C3H  AKR  CBA 
16  1.5  I  1.5  I  1.5  ] 
￿9  I  I  I 
1  I  1  I  1  I  1  ..........  .......  .........  ..........  ....  !,' 
0.5  ,  0.5  ,  o.s  Jar,  /  o s-I  ==  '  l 
I  &4~l  '  '  /  /  #,,,  | 
o  o  :  o  i/ 
0,5  I  -0.5  ￿9  I  0.5  I  0 
i  I  i  I  ,  I  l'l  i  I  ! 
0  1  2  3  0  1  2  3  0  1  2  3  0  1  2  3 
Stimulation  index  Stimulation  Index  Stimulation  Index 
C57BRxB  IO.BR  C57BRxC3H  C57BRxAKR  C57BRxCBA 
't  ,t,t  ' 1'r  =l't  '1 
=  q  4  :  14  = 
X  1  .......  1  ..........  ~1'  1  ..........  1"  1  .......  "1" ------ 
0.5  m  I  I  I  ==  05  ]--'-  ￿9  .p..:  05  :  o,  : 
~ ol  -'I"  ot  :  i ol  -*,  oi 
"~  I  ]  -o,~-'tl ~"  I  'i  t'~  !  ,  'l!/'e'6t/  I  t  It 
0  1  2  3  0  1  2  3  0  1  2  3  0  1  2  3 
Stimulation  Index  Stimulation  Index  Stimulation  Index  Stimulation  Index 
Figure 1.  Response  pattern of 
H-2  k mouse strains to  peptide 
Vfl 8.1/18-31. In vitro prolifera- 
tive response ofT cells from mice 
of  the indicated strains to different 
concentrations (3.5-30 #M) of  the 
peptide is shown. Each symbol 
represents the dose-response  curve 
of an individual mouse. For non- 
responder strains, the  enlarged 
lower left corner of  coordinates is 
shown  only  (no  responses oc- 
curred outside this range). Acpm 
is the difference, and stimulation 
index is the ratio between cpm in 
cultures with  and without  an- 
tigen. As a positive control, the 
response of each mouse to  the 
purified protein derivative of  tuber- 
culine was monitored. The ranges 
of responses (Aqm/$.L)  to  50 
/~g/ml of  PPD were the following: 
C57BR., 173799/33-274514/27; 
B10.BR, 92040/69-225288/53; 
C3H,  386000/20-500000/26; 
AKR,  269000/31-404000/38; 
CBA, 178200/99-344800/67; (C57BRxB10.BR)F1, 96752/68-291519/20; (C57BRxC3H)F1, 323500/31-339865/25; (C57BK￿  131604/ 
340-150060/485; (C57BRxCBA)FI,  117704/430-176098/554. 
secreted molecules indicate that they are folded into B-pleated sheet 
structures similar  to those of immunoglobulin V  domains (14). 
For stimulation of T cells, the soluble TCR constructs were used 
at  2-8/~M final concentration (corresponding to 50-200/~g/ml 
of single  chain VotVB). 
T Cell Lines, Clones, and Proliferation Assays.  9 d after immuni- 
zation, the regional lymph nodes were removed aseptically,  and 
single cell suspensions  were prepared.  Cells (2.5  x  10  s per well) 
were cultured in HL-1 medium (Ventrex,  Portland, Maine) in flat 
bottom 96-well microtiter plates with or without peptide antigen 
for 3 d. Proliferation  was measured by [3H]TdR incorporation (1 
/~Ci per well)  in triplicates  during the last  16 h of culture.  Cell 
lines were generated by culturing T cells (5  x  106/ml) in RPMI 
1640 medium with 10% FCS and 3.5/IM of peptide for 1 wk, 
and restimulating weekly with peptide, APC (2.5  x  106 cells per 
ml), and 2 ng/ml of recombinant Ib2. The stable lines were cloned 
by limiting dilution as described  previously (15). Proliferative  re- 
sponse  was tested by culturing T  cells from lines  (5  x  104 per 
well) or cloned T  cells (2  x  104 per well),  and syngeneic irradi- 
ated spleen cells (5  x  10  s per well) as APC in RPMI 1640 plus 
5% FCS or human AB serum, with or without different concen- 
trations of antigen for 3 d. Incorporation of [3H]TdR was mea- 
sured  during the last  6 h  of culture. 
Results 
Pattern ofT Cell Responsiveness to Peptide Vfl 8.1/18-31.  We 
have selected several 14-amino acid-long sequences that are 
unique to V/~ proteins not expressed in certain mouse strains 
caused by genomic deletion or somatic deletion of the corre- 
sponding T cells by endogenous superantigens (1, 2, 10). The 
corresponding synthetic peptides (mostly from V~8 6 and VB 
8.1)  were tested for immunogenicity in mouse strains ex- 
pressing or deleting the respective TCR VB. We have identified 
one peptide from the first hypervariable region of V~ 8.1, 
peptide 8.1/18-31,  which induced a T cell response in H-2  k 
mice. The pattern of responsiveness to this peptide is shown 
in  Fig.  1.  Of the  five  H-2  k strains  tested,  only C57BR 
mounted a T cell response to 8.1/18-31.  It should be noted 
that this is a strain with V~8.1 deleted from the germ line 
(10). The remaining strains (AKR, B10.BR,  CBA, C3H), 
as well as all (responder  x  nonresponder)F1 hybrids were 
nonresponders (i.e., responsiveness was recessive). T cell lines 
from the nonresponder strains remained nonresponder after 
in vitro restimulation with antigen and IL-2 (data not shown), 
suggesting that 8.1/18-31-specific T  cell precursors might 
have been absent. The response of C57BR T  cells to 8.1/ 
18-31 was not decreased upon mixing with C3H  (nonre- 
spender) T  cells primed with the same peptide, indicating 
that suppression was not involved in nonresponsiveness (data 
not shown). We also tested representative strains of the AKXL 
recombinant inbred series. The progenitor strains of AKXL 
are AKR carrying H-2  k on chromosome 17 and a full array 
of V~ genes on chromosome 6, as well as C57L that is H-2  b 
and carries the V~ a allele on chromosome 6  (i.e.,  50%  of 
VB genes including V/58 deleted; references 10, 16). According 
to the data in Table 1, the response clearly segregated with 
the presence of H-2 k, and the absence of V~ 8.1 expression 
in these strains.  To address the role of TCR more directly 
in the observed nonresponsiveness, we tested a TCR con- 
geneic strain with the VB' allele on B10.Q background (17), 
and a TCR-/5-deficient strain expressing no orb TCR at all 
(18), in comparison to the wild-type strains of origin. These 
strains were crossed with C57BR to provide H-2 k required 
for the response. The data demonstrated that responses oc- 
curred only in the V~' congeneic and the TCR-B-deficient 
strain but not in the wild-type controls (Table  1). Collec- 
tively, the data have demonstrated that the mechanism un- 
250  Self Tolerance to T Cell Receptor V/9 Sequences Table  1.  Response Pattern of AKXL Recombinant Inbred Strains, TCR  V~ Congeneic, and TCR  V~-deficient 
Strains to Peptide V~ 8.1/18-31 
V/~ 8.1  +  8.2 
Strain  H-2  expression*  Acpm range*  S.I.  range*  n 
AKXL-6  k  -  5,632-25,590  4.0-51.0  5 
AKXL-8  k  -  3,522-13,400  3.2-4.3  4 
AKXL-38  k  -  10,235-20,847  3.1-18.0  6 
AKXL-13  k  +  16-10,580  1.1-2.0  7 
AKXL-21  k  +  289-7,622  1.2-1.9  6 
AKXL-7  b  -  156-2,418  1.0-1.2  3 
C57LS  b  -  363-3,156  1.0-1.2  3 
(B10Q.VB  ~ x  C57BK)F1  (q  x  k)  -  60,842-104,361  4.8-26.0  4 
(B10.Q  x  C57BK)F1  (q  x  k)  +  1,679-17,312  1.1-2.0  5 
(TCKV/3-  x  C57BK)F1  (b  x  k)  -  27,651-144,900  3.7-22.0  5 
(C57BL/6  x  C57BK)F1  (b  x  k)  +  60-16,744  1.0-2.4  5 
* Highest and lowest secondary in vitro proliferative response of lymph node cells from the number of immunized animals (n) tested after 10 d of 
stimulation with 5 #m of 8.1/18-31 and 2 ng/ml of rlL-2  at antigen concentrations from 2.5 to 10 #M. 
t Tested by FACS  |  analysis (Becton Dickinson and Co.,  Mountain View, CA) of spleen cells using the VB 8.1  +  8.2-specific mAb KJ 16. 
S One of the parental strains of the AKXL series. Responsiveness of the other parental strain AKR is shown in Fig. 1. Ranges of positive control 
responses to  25  #g/ml  of PPD  (Acpm/S.l.)  were  the  following:  AKXL-6,  97728/39-153321/30; AKXL-8,  96773/20-162257/15;  AKXL-38, 
94631/6.2-165018/10; AKXL-13, 112369/22-124541/21; AKXL-21, 101732/27-107182/27; C57L (to 50 #g/ml PPD), 186203/25-286677/21; (B10.Q- 
V/~  ~ x  C57BR)F1, 76130/19.3-248692/24.5;  (B10.Q x  57BK)F1, 77622/13.4-223548/18.9;  (TCRV~  x  C57BR)F1, 105920/14.0-174947/29.2; 
(C57BL/6  x  C57BK)F1, 72501/12.5-204494/19.0. 
derlying nonresponsiveness to peptide 8.1/18-31 is self toler- 
ance to V3  8.1. 
Cross-reactivity of V~  8.1~18-31-specific T  Cells  with  V~ 
8.2/18-31.  Of the nonresponding  strains tested,  CBA and 
AKR are peculiar in that they do carry the V3 8.1 gene, but 
the protein is expressed only in very small amounts because 
of clonal deletion of V3 8.1 + T  cells by the endogenous su- 
perantigen  Mls-1 ~ (Mtv-7)  (1,  19).  Thus,  the  reasons  for 
nonresponsiveness of these two strains remained to be clarified. 
The failure of CBA and AKR mice to respond to 8.1/18-31 
suggested that self tolerance to the peptide operated, although 
the corresponding tolerogen was not present in large amounts, 
except in the thymus for a short period of ontogeny. How- 
ever, the fine specificity of T  cells primed to 8.1/18-31  sug- 
gested another  explanation.  As shown in Table 2,  these T 
cells fully cross-reacted with the corresponding VB 8.2 pep- 
tide, although they were antigen specific, in that they failed 
to respond to hen egg white lysozyme (HEL) 46-61,  an un- 
related peptide to which H-2  k mice are high responders (20). 
The observed cross-reactivity is not surprising, taken the high 
degree  of sequence  homology between  the  8.1/18-31  and 
8.2/18-31 peptides (they differ only in three amino acid posi- 
tions).  Thus,  although  the role of residual V/~ 8.1  protein 
(left after somatic deletion by Mtv-7) in tolerance induction 
Table  2.  Cross-reactivity of Vfl 8.1~18-31-specific T  Cells with V~ 8.2/18-31 
Proliferative response (A/cpm/S.I.) 
Peptide in culture*  Sequence  Line  1*  Line 2* 
V~  8.1/18-31  KVTLSCHQTNNHDY  29662/4.8  128157/7.8 
V~/8.2/18-31  KVTLSCNQTNNHNN  83889/11.7  337551/19.0 
HEL/46-61  NTDGSTDYG I LQ I NSR  -988/0.9  -6084/0.7 
* Used at  19 #M. 
T cell lines were derived from 8.1/18-31 immune C57BR mice. Nine lines were altogether tested with the same results. 
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APC 
Proliferative response (Acpm/S.I.) by clones* 
H-2 loci 
Strain  /( A E  D  No.  3  No.  46  No.  22  No.  67 
C57BR  k  k  k  k  234519/2174  53875/196  103703/382  117879/614 
B10.A(4R)  k  k  b  b  243368/526  32143/83  10724/40  65913/388 
B10.AQR  q  k  g  d  221479/669  34766/144  nt  nt 
B10.T(6R)  q  q  q  d  1208/5  646/5  nt  nt 
A.TL  s  k  g  d  nt  nt  22984/144  56469/317 
A.TH  $  s  $  d  nt  nt  237/1.7  111/0.8 
* Clones 3, 46, and 22 were derived from strain AKXL-38 and clone 67 from C57BR mice. Using a panel of anti-Vot and anti-BB antibodies (specific 
for Vcr  2,3.2,8,11, and V/3 2,3,4,5.1+5.2,6,7,8.1  +  8.2,9,10,11,12,13,14,17a), clone 3 typed V~/7 Vc~-blank, clone 22 VB14 Vc~-blank, and clones 
46 and 67 Vc~-VB-blank by immunofluorescence. All clones were TCtL~ +  , CD4 +, and CD8-. 
is not ruled  out formally, the lack of response in CBA and 
AKR mice is readily explained by cross-tolerance to VB 8.2 
that  is  expressed in  these  strains. 
Characterization ofT Cells Responding to Vfl 8.1/18-31.  We 
investigated the type of T  cell response induced by the VB 
8.1  peptide.  The MHC  restriction  of 8.1/18-31-specific  T 
cell clones was determined using spleen cells from the appro- 
priate intra-H-2  recombinant  strains  as APC.  The data  in 
Table  3  demonstrate  mapping  of the  MHC  restriction  to 
I-A  k. All clones characterized  thus  far were CD4 §  and c~ 
TCR +  (data  not  shown).  Polyclonal T  cell lines were also 
CD4 + and I-A  k restricted,  as shown by inhibition or deple- 
tion with the relevant mAb (anti-L3T4, and 14V18; data not 
shown). The 8.1/18-31-specific T  cells had no demonstrable 
cytotoxic activity against syngeneic T  or B cell blasts or B 
cell lymphoma in the presence of the peptide (data not shown). 
Reactivity of V~ Peptide-specific T Cells with a Soluble TCR 
Construct.  To establish a direct link between the T  cell re- 
sponse to peptide 8.1/18-31  (and 8.2/18-31)  and  the corre- 
sponding V~8 protein, we have investigated whether peptide- 
primed T  cells could recognize a soluble TCR construct (12, 
14), Vot4/VB8.2,  presented by syngeneic APC. The results 
in Table 3 demonstrate that this is indeed the case: both cloned 
and polyclonal T  cell lines have recognized peptides 8.1/18- 
31, 8.2/18-31,  and the soluble Vc~4/V~8.2 construct equally 
well,  but  failed to respond  to  the control  Vol4  construct. 
Thus, the immunogenic/tolerogenic  peptide appeared to be 
produced by processing of the V/~8.2 protein. Based on these 
results, it was conceivable that the detectability of tolerance 
may be critically dependent on the identity of the synthetic 
peptide with the one produced by processing of the relevant 
protein. This hypothesis was investigated by using an extended 
Table  4.  Reactivity of Vfl Peptide-specific T  Cells to a Soluble TCR  Construct 
Proliferative response (Acpm/S.I.)~ 
Clone 46s  Line 3 Sll  Line Ds~  Line 4g 
8.1/18-31  8.1/18-31  8.1/15-32  8.1/15-32"* 
Antigen*  AKXL-38  C57BR  C57BR  C3H 
sol.Va4/VB8.2  36204/178  23169/4.8  -534/0.9  -286/0.9 
sol.Va4  394/2.0  -155/1.0  -1688/0.6  -884/0.7 
8.1/18-31  53875/196  16618/3.8  3694/1.8  -468/0.8 
8.2/18-31  77663/282  12497/3.1  3437/1.8  128/1.0 
8.1/15-32  34733/127  13658/3.3  31955/8.6  22993/9.0 
* Proliferative response to 5 /zM of peptide and 8 /~M of soluble TCR construct is shown. 
* In the presence of irradiated C57BR  splenic APC. 
S The specficity and strain of origin of T cell lines are as indicated. 
IITwo cell lines were tested with the same results. 
~1 Two additional 8.1/15-32-specific lines generated from C57BR and B10.BR mice, respectively, gave the same results. 
** Peptide 8.1/15-32 has an NH2-terminal Thr-Gly-Gly and a COOH-terminal Met addition to 8.1/18-31. 
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in Table 4, both C57BR mice and C3H mice (the latter non- 
responder to 8.1/18-31) were able to respond to 8.1/15-32. 
However, T cells recognizing the extended peptide failed to 
respond to either the short Peptide or the soluble TCR con- 
struct.  Thus,  the extended peptide was probably not pro- 
duced by processing,  and consequently, was not subject to 
self tolerance. These results provide direct support to the hy- 
pothesis that  tolerance to the V/3 8.1 and VB 8.2 proteins 
is the cause of nonresponsiveness to the 18-31 VI3 peptides 
in  strains  expressing  these proteins  as self. 
Discussion 
The results presented herein have demonstrated self toler- 
ance to a germline-encoded variable portion of or/3 TCRs. 
The detection of tolerance seemed to depend on the identity 
of the probing synthetic TCR Peptide with the one produced 
from processing the relevant TCR protein. Probably because 
of this requirement, tolerance to synthetic TCR Peptides has 
not been demonstrated thus far, but several laboratories were 
able to show T  cell responses to long (usually 20met) syn- 
thetic TCR peptides (9,  21-24).  Our finding,  if generaliz- 
able, demonstrates that antigen receptors, with the possible 
exception of their somatically diversified portions  (i.e.,  so- 
matic mutations  in antibodies,  and the third  hypervariable 
region of TCR), are subject to tolerance,  similarly to other 
self proteins accessible to the immune system. The somati- 
cally diversified sequences of antigen  receptors may escape 
self tolerance, because they may not attain the concentration 
required for tolerance induction  (25).  Thus,  potential  net- 
work interactions could only be directed to such sequences, 
provided that  they are presented by the individual's  MHC 
molecules. 
These results also have implications for the therapeutic use 
of synthetic TCR peptides in autoimmune diseases  (9,  21, 
22). The reported beneficial effect of TCR peptides in au- 
toimmune disease models has been explained by the induc- 
tion of a downregulatory immune response against T  cells 
that express the relevant receptor and are involved in autoim- 
mune pathology (9).  Our present  results suggest that  a T 
cell response to a TCR peptide can only occur when the im- 
munizing peptide is not identical with a naturally processed 
tolerogenic TCR fragment. Consequently, a treatment with 
synthetic TCR peptides can have different outcomes. First, 
when the synthetic peptide corresponds to a tolerogenic frag- 
ment, no response and no therapeutic effect will ensue. Second, 
when the fragment corresponding to the immunogen is not 
produced at all by processing, a response will result, but it 
is likely to remain without therapeutic consequence. Indeed, 
this possibility has been demonstrated experimentally by Sun 
(26).  Third,  when the fragment  is produced in subtolero- 
genic amounts by processing,  the corresponding  synthetic 
peptide will induce an immune response that could affect the 
cells naturally presenting this sequence, in the first place, the 
T cells expressing the appropriate receptor. When the latter 
cells are involved in autoimmune pathology,  a response to 
them could modify the disease in two possible ways: down- 
regulation  with  a beneficial effect (9,  22),  or upregulation 
leading to exacerbation (27). Future research will have to iden- 
tify ways to direct the anti-TCR response toward beneficial 
effects. 
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